Non-Viral delivery of innovative therapeutics
Manuel Vega, CEO at AGS Therapeutics.
pp. 13-21
Summary
1. Viral-Based Delivery Systems
2. Lipid Nanoparticles (LNPs) as a Delivery System
3. Extracellular Vesicles: From Mammalian Origin to Microalgae-Derived Platforms
4. Microalgae Extracellular Vesicles (MEVs): A Next-Generation Non-Viral Delivery Platform
Acknowledgments
5. References
